Roszdravnadzor has given permission to the American pharmaceutical company Pfizer is conducting clinical trials of the effectiveness of the drug COVID-19 in Russia. On the state register of medicines drew attention “Vedomosti”.
The drug of the American pharmaceutical company is called Paxlovid – it is developed on the basis of a protease inhibitor and ritonavir. The medicine is available in capsules, which makes it possible to use it in outpatient treatment.
Pfizer said the drug could be used to prevent coronavirus and treat patients with severe illness. It reduces the risk of COVID-19 infection by 89 percent, the pharmaceutical company said.
The clinical trials will involve 90 Russians over 18 who come into contact with people with symptoms of COVID-19. Among them will be residents of the Moscow region, St. Petersburg, Barnaul, Smolensk and other cities.
Worldwide, according to Pfizer, 7,000 people are taking this drug in clinical trials.
Previously, Pfizer’s Russian direct investment scheme for booster vaccination – the third shot. The fund said that the increase in the number of people infected with the new COVID-19 strain in the United States and Israel indicates that mRNA vaccines need a heterogeneous booster to enhance and prolong the immune response.